Diagnostic efficacy of petand pet/ct for recurrent lung cancer: A meta-analysis

Acta Radiologica

Volumn 55, Issue 3, 2014, Pages 309-317

  He, Yan Qi ^a   Gong, Han Lin ^a   Deng, Yi Fu ^b   Li, Wei Min ^a  

^a SICHUAN UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Diagnosis; Integrated PET CT; Lung cancer; Meta analysis; PET; Recurrence

Indexed keywords

BIOLOGICAL ORGANS; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; IMAGING TECHNIQUES; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY;

CONVENTIONAL IMAGING; INTEGRATED PET/CT; LUNG CANCER; META-ANALYSIS; POSITRON EMISSION TOMOGRAPHY (PET); RECEIVER OPERATING CHARACTERISTICS; RECURRENCE; SYSTEMATIC SEARCHES;

DISEASES;

FLUORODEOXYGLUCOSE F 18; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EXAMINATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; META ANALYSIS; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSIS; INTEGRATED PET/CT; LUNG TUMOR; MULTIMODAL IMAGING; PET; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TUMOR RECURRENCE;

DIAGNOSIS; INTEGRATED PET/CT; LUNG CANCER; META-ANALYSIS; PET; RECURRENCE;

CONTRAST MEDIA; HUMANS; LUNG NEOPLASMS; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84900812442     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185113498536     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005.CA Cancer J Clin 2005;55:10-30.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001. Eur Respir J Suppl 2002;35:61s-70s.
4. Haberkorn U, Schoenberg SO. Imaging of lung cancer with CT, MRT and PET. Lung Cancer 2001;34 (Suppl. 3):S13-23.
5. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007;132 (Suppl. 3):355S-367S.
6. Chiu CH, Chern MS, Wu MH, et al. Usefulness of lowdose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg 2003;125:1300-1305.
7. Gorich J, Beyer-Enke SA, Flentje M, et al. Evaluation of recurrent bronchogenic carcinoma by computed tomography. Clinical Imaging 1990;14:131-137.
8. Libshitz HI, Sheppard DG. Filling in of radiation therapy- induced bronchiectatic change: a reliable sign of locally recurrent lung cancer. Radiology 1999;210:25-27.
9. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy- D-glucose. J Comput Assist Tomogr 1993;17:582-589.
10. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
11. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302-1305.
12. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105-112.
13. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
14. Onishi Y, Ohno Y, Koyama H, et al. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Eur J Radiol 2011;79:473-479.
15. Kanzaki R, Higashiyama M, Maeda J, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg 2010;10:1009-1014.
16. Cho S, Lee EB. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg 2010;139:1447-1451.
17. Isobe K, Hata Y, Takai Y, et al. Usefulness of fluoro- 2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol 2009;14:497-501.
18. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21.
19. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18FFDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-1646.
20. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-1613.
21. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376-1380.
22. Takenaka D, Ohno Y, Koyama H, et al. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol 2010;74:458-464.
23. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-139. (discussion 9-40).
24. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-382.
25. Lee J, Aronchick JM, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001;120:1791-1797.
26. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography- computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006;24:3333-3339.
27. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-162.
28. Satoh H, Ohtsuka M. PET/CT imaging in response evaluation of SCLC patients. Lung Cancer 2007;55:123-124.
29. Franzius C. FDG PET: advantages for staging the mediastinum? Lung Cancer 2004;45 (Suppl. 2):S69-74.